NuCana Resistant Melanoma Treatment Data Shows Providing Some Relief After Disappointing Colorectal Cancer Data, Stock Surges
NuCana Resistant Melanoma Treatment Data Shows Providing Some Relief After Disappointing Colorectal Cancer Data, Stock Surges
One of these patients, who had received two prior lines of PD-1 inhibitor-based therapy and had progressed on their latest treatment of ipilimumab plus nivolumab within two months, achieved a 55% reduction in tumor volume.On Saturday, NuCana plc (NASDAQ:NCNA) presented final data from the Phase 2 NuTide:701 study at the ESMO Congress on NUC-7738 in combination with Merck & Co Inc's (NYSE:MRK) Keytruda (pembrolizumab) for metastatic melanoma who were refractory to or had relapsed on prior PD-1 inhibitor therapy.
周六，纳斯达克上市公司NuCana plc (NASDAQ:NCNA)在ESMO大会上报告了NuTide:701第2期研究关于NUC-7738与默沙东公司(NYSE:MRK)的Keytruda (pembrolizumab)联合治疗转移性黑色素瘤患者的最终数据，这些患者对PD-1抑制剂治疗产生了耐药性或复发。
In this 12-patient cohort, most patients had received at least two prior lines of PD-1 inhibitor therapy.
在这12名患者的队列中，大多数患者至少接受过两种PD-1抑制剂治疗。
Nine out of twelve (75%) achieved disease control, including two patients who achieved Partial Responses.
12名患者中有9名(75%)实现了疾病控制，其中包括两名患者实现了部分缓解。
One of these patients, who had received two prior lines of PD-1 inhibitor-based therapy and had progressed on their latest treatment of ipilimumab plus nivolumab within two months, achieved a 55% reduction in tumor volume.
其中一名接受了两种PD-1抑制剂治疗并在最近两个月内因伊匹利姆单抗加尼伏马布治疗的疗效下降而进展的患者，肿瘤体积减少了55%。
Seven of the 12 patients had a progression-free survival time of over five months.
12名患者中有7名的无进展生存时间超过五个月。
Hugh Griffith, NuCana's Founder and CEO, said, "We are very excited to share these data on NUC-7738 in combination with pembrolizumab in PD-1 inhibitor refractory and resistant patients with melanoma. Outcomes in this patient population are very poor, with median progression-free survival of 2-3 months with the current standard of care, so we are very encouraged that the majority of patients who received this combination achieved a progression-free survival of more than five months."
NuCana的创始人兼首席执行官Hugh Griffith表示：“我们非常激动地分享NUC-7738与pembrolizumab联合治疗PD-1抑制剂耐药和抗药黑色素瘤患者的这些数据。这类患者的预后非常糟糕，目前的标准护理方案中位无进展生存期为2-3个月，因此我们非常鼓舞人心的是，接受这种联合治疗的大多数患者实现了超过五个月的无进展生存。”
In addition to achieving these encouraging efficacy signals, the combination of NUC-7738 and pembrolizumab had a favorable safety profile.
除了取得这些鼓舞人心的疗效信号外，NUC-7738与pembrolizumab联合治疗还具有良好的安全性。
The company says NUC-7738 can sensitize PD-1-resistant tumors to rechallenge with PD-1 inhibitors due to its ability to target multiple aspects of the tumor microenvironment (TME) via the disruption of RNA polyadenylation and subsequent changes to gene expression in cancer cells.
该公司表示NUC-7738能够通过靶向肿瘤微环境(TME)的RNA多聚腺苷化破坏及癌细胞基因表达变化，使PD-1耐药肿瘤对PD-1抑制剂再次挑战产生敏感性。
Data from tumor biopsies obtained before and after NUC-7738-based treatment demonstrated increases in genes related to antigen presentation and T-cell activation.
经过基于NUC-7738治疗前后肿瘤活检数据显示与抗原呈递和T细胞激活相关的基因增加。
In August, NuCana discontinued NuTide:323 study following a pre-planned initial analysis and recommendation from the NuTide:323 Study Steering Committee.
八月份，nucana根据NuTide:323研究中的预定初始分析和NuTide:323研究指导委员会的建议，终止了NuTide:323研究。
While there were prognostic imbalances favoring the control arm, the Steering Committee believed that the combination of NUC-3373 with leucovorin, irinotecan, and bevacizumab (NUFIRI+bev) was unlikely to achieve the study's primary objective of superior Progression-Free Survival compared to the control arm of 5-FU, leucovorin, irinotecan, and bevacizumab (FOLFIRI+bev) in the final analysis.
尽管存在有利于对照组的预后失衡，但指导委员会认为NUC-3373与亚叶酸、伊立替康和贝伐单抗（NUFIRI+bev）联合使用，不太可能实现该研究的主要目标，即在最终分析中较对照组的5-FU、亚叶酸、伊立替康和贝伐单抗（FOLFIRI+bev）具有更优越的无进展生存率。
Price Action: NCNA stock is up 166.50% at $6.62 during the premarket session at last check Monday.
股票类表现：在上周一的最后一次检查时，NCNA股价在盘前交易中上涨166.50%，报6.62美元。
- EXCLUSIVE: Gauzy To Showcase AI-Powered Driver Assistance System for Safer Commercial Trucks.
- 独家报道：Gauzy将展示用于更安全商用卡车的人工智能驾驶辅助系统。
